Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan

Hiroshi Isobe,1 Kiyoshi Mori,2 Koichi Minato,3 Hideki Katsura,4 Kazuko Taniguchi,5 Ashwini Arunachalam,6 Smita Kothari,6 Xiting Cao,6 Terufumi Kato7 1Department of Medical Oncology, KKR Sapporo Medical Center, Hokkaido, 2Department of Thoracic Diseases, Division of Thoracic Oncology, Tsuboi Cancer C...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Isobe H, Mori K, Minato K, Katsura H, Taniguchi K, Arunachalam A, Kothari S, Cao X, Kato T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	predictive biomarker health care resource use Japan non-small cell lung cancer treatment patterns Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a5e3f5208df244dcb37cf43942d2c5c6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a5e3f5208df244dcb37cf43942d2c5c6
record_format	dspace
spelling	oai:doaj.org-article:a5e3f5208df244dcb37cf43942d2c5c62021-12-02T07:56:38ZReal-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan1179-2728https://doaj.org/article/a5e3f5208df244dcb37cf43942d2c5c62017-10-01T00:00:00Zhttps://www.dovepress.com/real-world-practice-patterns-for-patients-with-advanced-non-small-cell-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Hiroshi Isobe,1 Kiyoshi Mori,2 Koichi Minato,3 Hideki Katsura,4 Kazuko Taniguchi,5 Ashwini Arunachalam,6 Smita Kothari,6 Xiting Cao,6 Terufumi Kato7 1Department of Medical Oncology, KKR Sapporo Medical Center, Hokkaido, 2Department of Thoracic Diseases, Division of Thoracic Oncology, Tsuboi Cancer Center Hospital, Fukushima, 3Department of Respiratory Medicine, Gunma Prefectural Cancer Center, Gunma, 4Division of Respiratory Medicine, Tokyo Women’s Medical University Yachiyo Medical Center, Chiba, 5Market Access, MSD K.K., Tokyo, Japan; 6Center for Observational & Real World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA; 7Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Kanagawa, Japan Background: Recommended therapies for advanced/metastatic non-small cell lung cancer (NSCLC) have changed with the advent of targeted therapies. The objectives of this retrospective chart review study were to describe treatment patterns, biomarker testing practices, and health care resource use for advanced NSCLC at 5 sites in Japan.Patients and methods: We studied anonymized medical record data of patients aged ≥18 years who initiated systemic therapy for newly diagnosed stage IIIB or IV NSCLC from January 2011 through June 2013. Data were analyzed descriptively by histology and mutation status. Overall survival was estimated using the Kaplan–Meier method. Results: We studied 175 patients, including 43 (25%), 129 (74%), and 3 (2%) with squamous, nonsquamous, and unknown NSCLC histology, respectively; 83% had stage IV NSCLC. Overall, 123 patients (70%) were male; the median age was 70 years (range, 47–86); and 33 (19%) were never-smokers. In the nonsquamous cohort, 105 (81%) and 25 (19%) of patients were tested for epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement, respectively; 44 (42%) had EGFR-positive NSCLC and 2 (8%) had ALK-positive NSCLC, including 26/46 (57%) women and 21/46 (46%) never-smokers. In the squamous cohort, 17 (40%) and 4 (9%), respectively, were tested; 1 EGFR-positive tumor was detected. After first-line therapy, 105 (60%) patients received second-line, and 54/105 (51%; or 31% overall) received third-line therapy. EGFR tyrosine kinase inhibitors were most commonly prescribed for EGFR-positive NSCLC across all lines. In the nonsquamous EGFR/ALK-negative/unknown cohort, most received first-line platinum combinations, particularly younger patients (78% ≥75 years vs 93% <75 years old). The average hospitalization was 21 days/admission. The median (95% CI) overall survival from start of first-line therapy was 9.9 months (7.6–11.7) for all patients and 17.9 months (9.9–24.4) for patients with EGFR/ALK-positive status.Conclusion: Biomarker testing is common for nonsquamous NSCLC at the 5 Japanese study sites. Treatment is personalized by mutation status and age, per guideline recommendations. Keywords: predictive biomarker, health care resource use, Japan, non-small cell lung cancer, systemic therapy, treatment patternsIsobe HMori KMinato KKatsura HTaniguchi KArunachalam AKothari SCao XKato TDove Medical Pressarticlepredictive biomarkerhealth care resource useJapannon-small cell lung cancertreatment patternsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 8, Pp 191-206 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	predictive biomarker health care resource use Japan non-small cell lung cancer treatment patterns Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	predictive biomarker health care resource use Japan non-small cell lung cancer treatment patterns Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Isobe H Mori K Minato K Katsura H Taniguchi K Arunachalam A Kothari S Cao X Kato T Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan
description	Hiroshi Isobe,1 Kiyoshi Mori,2 Koichi Minato,3 Hideki Katsura,4 Kazuko Taniguchi,5 Ashwini Arunachalam,6 Smita Kothari,6 Xiting Cao,6 Terufumi Kato7 1Department of Medical Oncology, KKR Sapporo Medical Center, Hokkaido, 2Department of Thoracic Diseases, Division of Thoracic Oncology, Tsuboi Cancer Center Hospital, Fukushima, 3Department of Respiratory Medicine, Gunma Prefectural Cancer Center, Gunma, 4Division of Respiratory Medicine, Tokyo Women’s Medical University Yachiyo Medical Center, Chiba, 5Market Access, MSD K.K., Tokyo, Japan; 6Center for Observational & Real World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA; 7Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Kanagawa, Japan Background: Recommended therapies for advanced/metastatic non-small cell lung cancer (NSCLC) have changed with the advent of targeted therapies. The objectives of this retrospective chart review study were to describe treatment patterns, biomarker testing practices, and health care resource use for advanced NSCLC at 5 sites in Japan.Patients and methods: We studied anonymized medical record data of patients aged ≥18 years who initiated systemic therapy for newly diagnosed stage IIIB or IV NSCLC from January 2011 through June 2013. Data were analyzed descriptively by histology and mutation status. Overall survival was estimated using the Kaplan–Meier method. Results: We studied 175 patients, including 43 (25%), 129 (74%), and 3 (2%) with squamous, nonsquamous, and unknown NSCLC histology, respectively; 83% had stage IV NSCLC. Overall, 123 patients (70%) were male; the median age was 70 years (range, 47–86); and 33 (19%) were never-smokers. In the nonsquamous cohort, 105 (81%) and 25 (19%) of patients were tested for epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement, respectively; 44 (42%) had EGFR-positive NSCLC and 2 (8%) had ALK-positive NSCLC, including 26/46 (57%) women and 21/46 (46%) never-smokers. In the squamous cohort, 17 (40%) and 4 (9%), respectively, were tested; 1 EGFR-positive tumor was detected. After first-line therapy, 105 (60%) patients received second-line, and 54/105 (51%; or 31% overall) received third-line therapy. EGFR tyrosine kinase inhibitors were most commonly prescribed for EGFR-positive NSCLC across all lines. In the nonsquamous EGFR/ALK-negative/unknown cohort, most received first-line platinum combinations, particularly younger patients (78% ≥75 years vs 93% <75 years old). The average hospitalization was 21 days/admission. The median (95% CI) overall survival from start of first-line therapy was 9.9 months (7.6–11.7) for all patients and 17.9 months (9.9–24.4) for patients with EGFR/ALK-positive status.Conclusion: Biomarker testing is common for nonsquamous NSCLC at the 5 Japanese study sites. Treatment is personalized by mutation status and age, per guideline recommendations. Keywords: predictive biomarker, health care resource use, Japan, non-small cell lung cancer, systemic therapy, treatment patterns
format	article
author	Isobe H Mori K Minato K Katsura H Taniguchi K Arunachalam A Kothari S Cao X Kato T
author_facet	Isobe H Mori K Minato K Katsura H Taniguchi K Arunachalam A Kothari S Cao X Kato T
author_sort	Isobe H
title	Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan
title_short	Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan
title_full	Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan
title_fullStr	Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan
title_full_unstemmed	Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan
title_sort	real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in japan
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/a5e3f5208df244dcb37cf43942d2c5c6
work_keys_str_mv	AT isobeh realworldpracticepatternsforpatientswithadvancednonsmallcelllungcancermulticenterretrospectivecohortstudyinjapan AT morik realworldpracticepatternsforpatientswithadvancednonsmallcelllungcancermulticenterretrospectivecohortstudyinjapan AT minatok realworldpracticepatternsforpatientswithadvancednonsmallcelllungcancermulticenterretrospectivecohortstudyinjapan AT katsurah realworldpracticepatternsforpatientswithadvancednonsmallcelllungcancermulticenterretrospectivecohortstudyinjapan AT taniguchik realworldpracticepatternsforpatientswithadvancednonsmallcelllungcancermulticenterretrospectivecohortstudyinjapan AT arunachalama realworldpracticepatternsforpatientswithadvancednonsmallcelllungcancermulticenterretrospectivecohortstudyinjapan AT kotharis realworldpracticepatternsforpatientswithadvancednonsmallcelllungcancermulticenterretrospectivecohortstudyinjapan AT caox realworldpracticepatternsforpatientswithadvancednonsmallcelllungcancermulticenterretrospectivecohortstudyinjapan AT katot realworldpracticepatternsforpatientswithadvancednonsmallcelllungcancermulticenterretrospectivecohortstudyinjapan
_version_	1718399118034862080

Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan

Ejemplares similares